TFB 30: Entwicklung und klinische Evaluation eines neuen bispezifischen Moleküls zur Behandlung von Patienten mit Hodgkin-Lymphomen

在前两年，计划在体外鉴定针对CD30抗原的新的人类双特异性构建物。这些构建物基于Medarex公司的人抗cd64抗体H22和一种尚未确定的抗cd30抗体。双特异性结构的临床前评估也将包括测试，以确定其临床应用的安全性。所有的科研工作都将与medac GmbH和Medarex公司合作完成。第三年（2003年），计划进行i期临床研究，随后可能进行ii期研究。该项目的最终目的是在iii期研究中评估一线治疗霍奇金病的双特异性结构。

For the first two years, the in vitro characterization of new human bispecific constructs targeting the CD30 antigen is planned. The constructs are based on the human anti-CD64 antibody H22 from Medarex Inc. and on an anti-CD30 antibody, that has yet to be defined. The preclincal evaluation of the bispecific construct will include also tests to determine the safety of its clinical application. All the scientific work will be done in cooperation with the companies medac GmbH and Medarex Inc. For the third year (2003), a clinical phase-I is planned, that could be followed by a phase-II study. The final aim of this project is the evaluation of a bispecific construct for the first-line treatment of Hodgkin´s disease in a phase-III study.